Predict your next investment

Corporation
HEALTHCARE | Biotechnology
sana.com

See what CB Insights has to offer

Founded Year

2018

Stage

IPO | IPO

Total Raised

$700M

Date of IPO

2/4/2021

Market Cap

3.94B

Stock Price

19.04

About Sana Biotechnology

Sana Biotechnology (NASDAQ: SANA) focuses on creating and delivering engineered cells as medicines for patients.

Sana Biotechnology Headquarter Location

188 East Blaine Street Suite 400

Seattle, Washington, 98102,

United States

206-701-7914

Latest Sana Biotechnology News

Sana Biotechnology Inks Long-Term Biomanufacturing Lease

Jul 19, 2021

Source: Tek Image/Science Photo Library/Getty Images July 19, 2021 Share Seattle-based Sana Biotechnology signed a lease agreement to develop a 163,000 ft2 manufacturing facility in Fremont, CA. The facility will support the manufacture of Sana’s late-stage clinical development and early commercial product candidates across the multiple technologies in Sana’s pipeline, according to Steve Harr, MD, president and CEO. “Manufacturing remains a key bottleneck to the development and broad accessibility of cell- and gene-based medicines. This facility is a key component in enabling our aspirations to rapidly innovate, consistently manufacture, and scale production of these medicines,” said Harr. “Sana is making significant investments to create the scientific insights, supply chain stability, and operational capabilities to transform the potentially disruptive scientific insights of the cell and gene therapy field into important medicines for patients.” The facility will be designed to provide manufacturing capabilities across Sana’s portfolio, including allogeneic T cell, viral vector, and pluripotent stem cell production. The Fremont location allows access to a strong biotechnology talent base. Sana, which is focused on creating and delivering engineered cells as medicines for patients, also intends to work with contract manufacturing partners to advance its product candidates to the clinic as early as next year. Share

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sana Biotechnology

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sana Biotechnology in 3 CB Insights research briefs, most recently on Aug 4, 2020.

Expert Collections containing Sana Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sana Biotechnology is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sana Biotechnology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sana Biotechnology Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.